Kanada - angličtina - Health Canada

apotex inc - bevacizumab - solution - 100mg - bevacizumab 100mg - antineoplastic agents

Kanada - angličtina - Health Canada

apotex inc - bevacizumab - solution - 400mg - bevacizumab 400mg - antineoplastic agents

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - bevacizumab, quantity: 100 mg - injection, concentrated - excipient ingredients: trehalose dihydrate; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; polysorbate 20; purified water - metastatic colorectal cancer,vegzelma (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer.,locally recurrent or metastatic breast cancer,vegzelma (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated. (see section 5.1 clinical trials).,advanced, metastatic or recurrent non-squamous non-small cell lung cancer (nsclc),vegzelma (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous, non- small cell lung cancer.,advanced and/or metastatic renal cell cancer,vegzelma (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer.,grade iv glioma,vegzelma (bevacizumab) as a single agent, is indicated for the treatment of patients with grade iv glioma after relapse or disease progression after standard therapy, including chemotherapy.,epithelial ovarian, fallopian tube or primary peritoneal cancer,vegzelma (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with advanced (figo stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer.,recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer,vegzelma (bevacizumab), in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with first recurrence of platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other vegf-targeted angiogenesis inhibitors. vegzelma (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens, and have not received any prior anti-angiogenic therapy including bevacizumab.,cervical cancer,vegzelma (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. vegzelma (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - bevacizumab, quantity: 400 mg - injection, concentrated - excipient ingredients: trehalose dihydrate; dibasic sodium phosphate; purified water; monobasic sodium phosphate monohydrate; polysorbate 20 - metastatic colorectal cancer,vegzelma (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer.,locally recurrent or metastatic breast cancer,vegzelma (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated. (see section 5.1 clinical trials).,advanced, metastatic or recurrent non-squamous non-small cell lung cancer (nsclc),vegzelma (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous, non- small cell lung cancer.,advanced and/or metastatic renal cell cancer,vegzelma (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer.,grade iv glioma,vegzelma (bevacizumab) as a single agent, is indicated for the treatment of patients with grade iv glioma after relapse or disease progression after standard therapy, including chemotherapy.,epithelial ovarian, fallopian tube or primary peritoneal cancer,vegzelma (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with advanced (figo stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer.,recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer,vegzelma (bevacizumab), in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with first recurrence of platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other vegf-targeted angiogenesis inhibitors. vegzelma (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens, and have not received any prior anti-angiogenic therapy including bevacizumab.,cervical cancer,vegzelma (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. vegzelma (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

samsung bioepis au pty ltd - bevacizumab, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium acetate trihydrate; polysorbate 20; water for injections; trehalose dihydrate; acetic acid - metastatic colorectal cancer,onbevzi (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer.,locally recurrent or metastatic breast cancer,onbevzi (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated.,advanced, metastatic or recurrent non-squamous non-small cell lung cancer (nsclc),onbevzi (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous, non-small cell lung cancer.,advanced and/or metastatic renal cell cancer,onbevzi (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer.,grade iv glioma,onbevzi (bevacizumab) as a single agent, is indicated for the treatment of patients with grade iv glioma after relapse or disease progression after standard therapy, including chemotherapy.,epithelial ovarian, fallopian tube or primary peritoneal cancer,onbevzi (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with advanced (figo stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer.,recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer,onbevzi (bevacizumab), in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with first recurrence of platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other vegf-targeted angiogenesis inhibitors.,onbevzi (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens and have not received any prior anti-angiogenic therapy including bevacizumab.,cervical cancer,onbevzi (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. onbevzi (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

samsung bioepis au pty ltd - bevacizumab, quantity: 400 mg - injection, concentrated - excipient ingredients: sodium acetate trihydrate; polysorbate 20; water for injections; trehalose dihydrate; acetic acid - metastatic colorectal cancer,onbevzi (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer.,locally recurrent or metastatic breast cancer,onbevzi (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated.,advanced, metastatic or recurrent non-squamous non-small cell lung cancer (nsclc),onbevzi (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous, non-small cell lung cancer.,advanced and/or metastatic renal cell cancer,onbevzi (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer.,grade iv glioma,onbevzi (bevacizumab) as a single agent, is indicated for the treatment of patients with grade iv glioma after relapse or disease progression after standard therapy, including chemotherapy.,epithelial ovarian, fallopian tube or primary peritoneal cancer,onbevzi (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with advanced (figo stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer.,recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer,onbevzi (bevacizumab), in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with first recurrence of platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other vegf-targeted angiogenesis inhibitors.,onbevzi (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens and have not received any prior anti-angiogenic therapy including bevacizumab.,cervical cancer,onbevzi (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. onbevzi (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

Singapur - angličtina - HSA (Health Sciences Authority)

roche singapore pte. ltd. - bevacizumab - infusion, solution concentrate - 25mg - bevacizumab 25mg

Singapur - angličtina - HSA (Health Sciences Authority)

roche singapore pte. ltd. - bevacizumab - infusion, solution concentrate - 400mg - bevacizumab 400mg

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - bevacizumab - solution for infusion - 25mg/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - bevacizumab - solution for infusion - 25mg/1ml